Rocket Pharmaceuticals (RCKT) Price & Analysis

Compare

1,650 Followers

RCKT Stock Chart & Stats

$2.84

-$0.69(-5.46%)

At close: Jan 08 4:00 PM EST

$2.84

-$0.69(-5.46%)

Day’s Range― - ―

52-Week Range$2.19 - $15.01

Previous CloseN/A

Volume339.48K

Average Volume (3M)2.60M

Market Cap

$311.68M

Enterprise Value$166.01M

Total Cash (Recent Filing)$222.76M

Total Debt (Recent Filing)$25.05M

Price to Earnings (P/E)―

Beta1.49

Next Earnings

Mar 02, 2026

EPS Estimate

-0.43

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.45

Shares Outstanding108,222,230

10 Day Avg. Volume2,423,451

30 Day Avg. Volume2,595,621

Financial Highlights & Ratios

PEG Ratio0.71

Price to Book (P/B)2.57

Price to Sales (P/S)0.00

P/FCF Ratio-5.53

Enterprise Value/Market Cap0.53

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-65.38

Enterprise Value/Ebitda-0.73

Forecast

1Y Price Target

$9.83

Price Target Upside246.13% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering9

EPS Forecast (FY)-2.05

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessThe data from the first three patients in the Ph1 study of RP-A601 demonstrated a consistent and significant decrease in arrhythmia burden, and stabilization or improvement in both right ventricular function and patients' quality of life from RP-A601 treatment.

FDA Approval PathwayAn agreement with the FDA on an accelerated approval pathway for RP-A601 is seen as possible based on a favorable clinical profile and the precedent of RP-A501 for Danon disease.

Regulatory ProgressThe FDA lifted the clinical hold on the pivotal Ph2 study of RP-A501 in Danon disease, removing a major hurdle for Rocket Pharma.

Bears Say

Clinical HoldRP-A501 program in Danon disease is currently on clinical hold in the middle of a pivotal Ph2 study.

Rocket Pharmaceuticals News

Amazon downgraded, Alphabet upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

3d ago

Rocket Pharmaceuticals price target lowered to $8 from $10 at BofA

BofA lowered the firm’s price target on Rocket Pharmaceuticals (RCKT) to $8 from $10 and keeps a Buy...

3d ago

RCKT

Rocket Pharmaceuticals downgraded to Underweight from Neutral at JPMorgan

JPMorgan downgraded Rocket Pharmaceuticals (RCKT) to Underweight from Neutral without a price target The firm believes Rocket has...

3d ago

RCKT

Rocket Pharmaceuticals reports Q3 EPS (45c), consensus (52c)

Cash, cash equivalents and investments as of September 30, 2025, were $222.8 million. Rocket expects such resources, excluding...

15d ago

RCKT

Buy Rating for Rocket Pharmaceuticals: Strategic Progress and Strong Financial Position Drive Positive Outlook

In a report released today, Cory Jubinville, PhD from LifeSci Capital maintained a Buy rating on Rocket Pharmaceuticals,...

14d ago

RCKT

Rocket Pharmaceuticals Reports Q3 2025 Financial Results

Rocket Pharma ( ($RCKT) ) has released its Q3 earnings. Here is a breakdown of the information Rocket...

15d ago

RCKT

RCKT Upcoming Earnings Report: What to Expect?

Rocket Pharma (RCKT) is scheduled to report 3rd quarter earnings on 11/06/2025. Regarding Q3 estimates, Wall Street analysts...

17d ago

RCKT

Rocket Pharma’s Danon Disease Study: A Strategic Move in Genetic Cardiomyopathy

Rocket Pharma (($RCKT)) announced an update on their ongoing clinical study. Rocket Pharmaceuticals is conducting an observational study...

25d ago

RCKT

Rocket Pharma’s Gene Therapy Study for Danon Disease: A Potential Game-Changer

Rocket Pharma (($RCKT)) announced an update on their ongoing clinical study. Rocket Pharmaceuticals is conducting a Phase 2...

25d ago

RCKT

Rocket Pharma’s PKP2-ACM Study: A Step Forward in Cardiomyopathy Research

Rocket Pharma (($RCKT)) announced an update on their ongoing clinical study. Rocket Pharmaceuticals is conducting a study titled...

25d ago

RCKT

Rocket Pharma’s New Gene Therapy Trial: A Potential Game-Changer for Cardiomyopathy

Rocket Pharma (($RCKT)) announced an update on their ongoing clinical study. Rocket Pharmaceuticals (RCKT) is initiating a Phase...

25d ago

RCKT

Insider Moves: Rocket, Fair Isaac, Galaxy, Westinghouse, Fastenal

Insiders have been trading these 5 stocks: (($RCKT)), (($FICO)), (($TSE:GLXY)), (($WAB)) and (($FAST)). Here is a breakdown of...

1M ago

WAB

FAST

Promising Developments in Rocket Pharmaceuticals’ KRESLADI Gene Therapy Boost Buy Rating

Rocket Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Cory Jubinville, PhD...

1M ago

RCKT

Promising Future for Rocket Pharmaceuticals: Buy Rating Affirmed on Kresladi’s Progress and Potential

William Blair analyst Sami Corwin has maintained their bullish stance on RCKT stock, giving a Buy rating today....

1M ago

RCKT

RCKT FAQ

What was Rocket Pharmaceuticals’s price range in the past 12 months?

Rocket Pharmaceuticals lowest stock price was $2.19 and its highest was $15.01 in the past 12 months.

What is Rocket Pharmaceuticals’s market cap?

Rocket Pharmaceuticals’s market cap is $311.68M.

When is Rocket Pharmaceuticals’s upcoming earnings report date?

Rocket Pharmaceuticals’s upcoming earnings report date is Mar 02, 2026 which is in 101 days.

How were Rocket Pharmaceuticals’s earnings last quarter?

Rocket Pharmaceuticals released its earnings results on Nov 06, 2025. The company reported -$0.45 earnings per share for the quarter, beating the consensus estimate of -$0.496 by $0.046.

Is Rocket Pharmaceuticals overvalued?

According to Wall Street analysts Rocket Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Rocket Pharmaceuticals pay dividends?

Rocket Pharmaceuticals does not currently pay dividends.

What is Rocket Pharmaceuticals’s EPS estimate?

Rocket Pharmaceuticals’s EPS estimate is -0.43.

How many shares outstanding does Rocket Pharmaceuticals have?

Rocket Pharmaceuticals has 108,222,230 shares outstanding.

What happened to Rocket Pharmaceuticals’s price movement after its last earnings report?

Rocket Pharmaceuticals reported an EPS of -$0.45 in its last earnings report, beating expectations of -$0.496. Following the earnings report the stock price went down -1.858%.

Which hedge fund is a major shareholder of Rocket Pharmaceuticals?

Currently, no hedge funds are holding shares in RCKT

Rocket Pharmaceuticals Stock Smart Score

Underperform

Fundamentals

Return on Equity

-74.88%

Trailing 12-Months

Asset Growth

-6.52%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc. (RCKT) is a clinical-stage biotechnology company focused on developing first-in-class gene therapies for rare and devastating diseases. The company operates in the pharmaceutical sector, primarily targeting inherited genetic disorders with high unmet medical needs. Rocket Pharmaceuticals leverages its proprietary lentiviral vector platform to develop gene therapies aimed at providing long-lasting and potentially curative treatments for patients.

Rocket Pharmaceuticals (RCKT) Earnings & Revenues

Historic Earnings Reports

RCKT Stock 12 Month Forecast

Average Price Target

$9.83

▲(246.13% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","5":"$5","9":"$9","13":"$13","17":"$17"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$16.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9.83,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,5,9,13,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.77,4.71076923076923,5.651538461538461,6.592307692307692,7.533076923076923,8.473846153846154,9.414615384615384,10.355384615384615,11.296153846153846,12.236923076923077,13.177692307692308,14.118461538461538,15.05923076923077,{"y":16,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.77,4.236153846153846,4.702307692307692,5.168461538461539,5.634615384615385,6.100769230769231,6.566923076923077,7.033076923076923,7.49923076923077,7.965384615384616,8.431538461538462,8.897692307692308,9.363846153846154,{"y":9.83,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.77,4.018461538461539,4.266923076923077,4.515384615384615,4.763846153846154,5.012307692307692,5.260769230769231,5.509230769230769,5.757692307692308,6.006153846153846,6.254615384615384,6.503076923076923,6.751538461538461,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":16.98,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.41,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.57,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.74,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.45,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.81,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.86,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.77,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.59,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.99,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.24,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.16,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.77,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >